Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

665 ARTÍCULOS , VIENDO DEL 391 AL 405

Review of triazole scaffolds for treatment and diagnosis of Alzheimer's disease

Li Q, Qi S, Liang J, Tian Y, He S, Liao Q, Xing S, Han L, Chen X.

Chem Biol Interact. 2023 Sep 1;382:110623. doi: 10.1016/j.cbi.2023.110623. Epub 2023 Jul 13.

Trial of Solanezumab in Preclinical Alzheimer's Disease

Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team.

N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17.

Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer's Disease Drug Development

Bachman SL, Blankenship JM, Busa M, Serviente C, Lyden K, Clay I.

J Alzheimers Dis. 2023;95(2):379-389. doi: 10.3233/JAD-230152.

The Sigma Receptors in Alzheimer's Disease: New Potential Targets for Diagnosis and Therapy

Wang T, Jia H.

Int J Mol Sci. 2023 Jul 27;24(15):12025. doi: 10.3390/ijms241512025.

Advanced brain imaging for the diagnosis of Alzheimer disease

Wang YT, Rosa-Neto P, Gauthier S.

Curr Opin Neurol. 2023 Oct 1;36(5):481-490. doi: 10.1097/WCO.0000000000001198. Epub 2023 Aug 3.

Current emerging novel therapies for Alzheimer's disease and the future prospects of magneto-mechanical force therapy

Shen Y, Wang M, Li S, Yang J.

J Mater Chem B. 2023 Oct 11;11(39):9404-9418. doi: 10.1039/d3tb01629c.

Advancements in the Application of Nanomedicine in Alzheimer's Disease: A Therapeutic Perspective

Puranik N, Yadav D, Song M.

Int J Mol Sci. 2023 Sep 13;24(18):14044. doi: 10.3390/ijms241814044.

The Association Between Herpes Simplex Virus and Alzheimer's Disease: A Systematic Review

Cohen M, Austin E, Bradu S, Jagdeo J.

J Drugs Dermatol. 2023 Oct 1;22(10):1046-1052. doi: 10.36849/JDD.6785.

Applications of Nanoparticles in Alzheimer's Disease

Liu Y, Shen Y.

J Alzheimers Dis. 2023;96(2):459-471. doi: 10.3233/JAD-230098.

Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease

Cohen S, van Dyck CH, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer LD.

J Prev Alzheimers Dis. 2023;10(4):771-777. doi: 10.14283/jpad.2023.123.

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia

Yassine HN, Arellanes IC, Mazmanian A, De La Cruz L, Martinez J, Contreras L, Kono N, Liu BS, Badie D, Bantugan MA, Grindon A, Urich T, D'Orazio L, Emmanuel BA, Chui HC, Mack WJ, Harrington MG, Braskie MN, Schneider LS.

J Prev Alzheimers Dis. 2023;10(4):810-820. doi: 10.14283/jpad.2023.77.

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group.

N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.

The Major Hypotheses of Alzheimer's Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment

Cáceres C, Heusser B, Garnham A, Moczko E.

Cells. 2023 Nov 21;12(23):2669. doi: 10.3390/cells12232669.

Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease

Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, Maldonado J, Donahue MJ, Schultz D, Coyne TM, Charidimou A, Schrag M.

Nat Commun. 2023 Dec 12;14(1):8220. doi: 10.1038/s41467-023-43933-5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias